NYSE

Updated Oct 30, 7:59 PM ET

BHVN

Biohaven Ltd.
$15.42CS band Weak

−$1.07 (6.49%) Fri · Closed $15.42

$0.00 (0.00%) ☾ After Hours

Oct 30, 7:59 PM ET

About BHVN

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

News

1 latest

No direct coverage yet · Showing articles that mention BHVN

GlobeNewswire Inc.

Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development

Bexorg, a precision neurology company, received up to $28.3 million in funding from ARPA-H to extend its BrainEx perfusion technology from 24 hours to two weeks. This advancement will enable longitudinal studies of human brain pharmacology and drug responses, potentially reducing CNS drug development attrition by providing richer human brain data for AI model training and clinical trial design.

Headlines open the publisher's site.